Adalimumab Expectations Revised In The Wake Of Amgen Launch

Analysts Outline Predictions And Weigh In On Key Questions Yet To Be Answered

 
• By Dave Wallace
  
Retaining market share in the face of competition
Analysts expect AbbVie to retain the vast majority of volume share in 2023 • Source: Shutterstock

More from Biosimilars

More from Products